Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Rod Baber

Prof Rod Baber

Menopausal Hormone Therapy - What Dose of Estrogen is Best?

Dr Adam Nelson

Dr Adam Nelson

Cardiovascular Benefits of GLP1s – New Evidence

Dr Kathleen McNamee, Prof Sonia Grover

Dr Kathleen McNamee, Prof Sonia Grover

Oral Contraceptive Pill in Teens

Prof Andrew Sindone

Prof Andrew Sindone

RSV and the Heart

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Martin MacDonald

expert

Dr Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Date published: 20 November 2023